Research ArticleDrug Discovery and Translational Medicine
Nonclinical Characterization of the HIF-Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment for Anemia of Chronic Kidney Disease
Ughetta del Balzo, Pierre E Signore, Gail Walkinshaw, Todd W Seeley, Mitchell C Brenner, Qingjian Wang, Guangjie Guo, Michael P Arend, Lee A Flippin, F. Aisha Chow, David C Gervasi, Christian H Kjaergaard, Ingrid Langsetmo, Volkmar Guenzler, David Y Liu, Steve J Klaus, Al Lin and Thomas B Neff
Journal of Pharmacology and Experimental Therapeutics June 2, 2020, jpet.120.265181; DOI: https://doi.org/10.1124/jpet.120.265181
Ughetta del Balzo
FibroGen, Inc
Pierre E Signore
FibroGen, Inc
Gail Walkinshaw
FibroGen, Inc
Todd W Seeley
FibroGen, Inc
Mitchell C Brenner
FibroGen, Inc
Qingjian Wang
FibroGen, Inc
Guangjie Guo
FibroGen, Inc
Michael P Arend
FibroGen, Inc
Lee A Flippin
FibroGen, Inc
F. Aisha Chow
FibroGen, Inc
David C Gervasi
FibroGen, Inc
Christian H Kjaergaard
FibroGen, Inc
Ingrid Langsetmo
FibroGen, Inc
Volkmar Guenzler
FibroGen, Inc
David Y Liu
FibroGen, Inc
Steve J Klaus
FibroGen, Inc
Al Lin
FibroGen, Inc
Thomas B Neff
FibroGen, Inc
Data Supplement
- Supplemental Data -
4 supplemental figures, 1 table.